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INTRODUCTION
The importance for health of regulating adaptive immune 
responses is well established, particularly the roles of regu-
latory lymphocyte populations [1], but the contribution of non- 
immune cells to this control is less well defined. For example, 
although the primary role of red blood cells (RBC) is gaseous 
transport, it is an open possibility that they have other functions, 
in particular the ability to modulate the activity of immune cells 
within their microenvironment [2]. RBC are by far the most 
abundant cell type in the bloodstream [3], where they are in 
continuous contact with circulating leucocytes and thus have 
the opportunity to deliver regulatory signals. In contrast to the 
extensive literature describing the immune effects of platelets 
[4], there are very few reports of the interactions of RBC with 
innate or adaptive immunity. Evidence has emerged that RBC 
can indeed inhibit immune cells such as neutrophils [5] and T 
cells [6], but little is known of their effects on human B cells.
B cells make up approximately 15% of circulating lympho-
cytes, and in addition to providing antibody responses, they 
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Abstract
Non- immune cells are increasingly recognized as important in regulating immunity, but 
the role of red blood cells (RBC) remains relatively unexplored, despite their abundance 
in the circulation and a cell surface rich in potential ligands. Here, we determine whether 
RBC influence the activation state of human B cells. Separation of RBC from peripheral 
blood mononuclear cells increased B- cell expression of HLA- DR/DP/DQ, whilst recon-
stitution reduced the levels of B- cell activation markers HLA- DR/DP/DQ, CD86, CD69 
and CD40, as well as decreasing proliferative responses and IgM secretion. Inhibition 
of B cells required contact with RBC and was abrogated by either removal of sialic 
acids from RBC or blocking the corresponding lectin receptor CD22 on B cells. Chronic 
lymphocytic leukaemia B cells express low levels of CD22 and were less susceptible to 
inhibition by RBC, which may contribute to their activated phenotype. Taken together, 
the results identify a novel mechanism that may suppress inappropriate responsiveness of 
healthy B cells whilst circulating in the bloodstream.
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function as professional antigen- presenting cells (APCs), capa-
ble of activating antigen- specific T cells [7]. It is an important 
question as to how B cells are regulated to ensure efficient and 
effective protection against pathogens, whilst constraining in-
appropriate activation that can lead to dysfunctional responses 
or autoimmune disease [8]. Uncontrolled proliferation and an 
activated phenotype are also hallmarks of B- cell malignancies 
such as chronic lymphocytic leukaemia (CLL) [9].
Activation, proliferation and differentiation of adaptive im-
mune cells are normally limited to secondary lymphoid organs 
(SLOs), such as the spleen and lymph nodes. The architecture 
of SLO is highly organized to optimize the interactions be-
tween B cells, T cells, APC and cognate antigen, providing 
an appropriate environment for the initiation and control of 
immune responses. Naïve B cells migrate through SLO for 
up to 24#h, and, if not activated, then return to the circulation 
to be taken back to SLO [10]. Activation by antigen in SLO 
and interactions with specific helper T cells lead to germinal 
centre formation, where B cells with high- affinity antibodies 
can differentiate into plasma and memory cells [11].
Given the importance of SLO to the tight co- ordination of 
efficient, appropriate adaptive immune responses, it seems 
likely there are mechanisms to constrain B- cell activation in 
peripheral blood, whilst transiting between SLOs. RBC are 
plausible candidates to deliver inhibitory signals to B cells 
whilst in the bloodstream, given both their abundance and 
decoration with a complex array of surface molecules that 
is rich in potential ligands [12]. Here, we test the hypothe-
sis that contact with RBC suppresses activation of human 
B cells. The results reveal that RBC do inhibit B cells, in-
cluding their expression of activation markers, proliferative 
responses and secretion of immunoglobulin, and that a key 
mediator of these effects is the recognition of sialic acids on 
the RBC surface by the B- cell lectin CD22.
MATERIALS AND METHODS
Patients and donors
All donors and patients gave informed consent, and the 
study was approved by the North- East of Scotland Research 
Ethics Committee (Application numbers: 14/NS/0009 and 
13/NS/0159). Blood samples from healthy volunteers, and 
from patients with CLL attending Aberdeen Royal Infirmary, 
were collected by venepuncture into lithium heparin- coated 
Vacutainers (Greiner Bio- One). Details of patients with CLL 
are summarized in Table 1.
Preparation of cells
Peripheral blood mononuclear cells (PBMC) and RBC were 
isolated from whole blood by density gradient centrifuga-
tion on Histopaque- 1077 (Sigma- Aldrich). The granulocyte 
layer was excluded when collecting RBC from the gradient, 
with flow cytometry confirming that the resulting prepara-
tion contains >99·99% cells staining for the RBC marker 
T A B L E  1  Details of patients with CLL
Sex Age Binet stage Previous therapy Current therapy Autoimmune status
M C Ibrutinib, FCR, R- bendamustine Corticosteroids AIHA, previous PRCA
M 78 A None None None
M 56 A None None None
M 64 B None None None
M 80 A None None None
M 62 A None Corticosteroids AIHA
F 76 B None Corticosteroids AIHA
M 58 A None None None
M 58 C FCR None None
M 65 A None Corticosteroids AIHA
M 52 A None None None
F 67 C FCR, FC, rituximab, idelalisib None None
M 52 A None None None
F 72 A FCR None None
M 69 A None None None
F 76 C None Corticosteroids AIHA
Abbreviations: AIHA, autoimmune haemolytic anaemia; F, female; FC, fludarabine and cyclophosphamide; FCR, fludarabine, cyclophosphamide and rituximab; M, 
male; PRCA, pure red cell aplasia.
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glycophorin A (CD235a). CD19+ B cells were purified from 
PBMC using the Pan B- Cell Isolation Kit (Miltenyi Biotec), 
which labels other leucocytes with biotinylated antibodies 
to allow their depletion by Anti- Biotin MicroBeads as per 
the manufacturer's instructions. Magnetic beads (Miltenyi 
Biotec) coated with anti- human CD4 were used to isolate 
CD4+ T cells from PBMC as directed by the manufacturer. 
The purity of isolated CD19+ B cells and CD4+ T cells was 
confirmed by flow cytometry with, as reported in [13], >90% 
of selected cells CD19- or CD4- positive as appropriate.
Cell culture
Peripheral blood mononuclear cells or isolated CD19+ B 
cells were cultured at a concentration of 1·25# $# 106# cells/
ml in the alpha modification of Eagle's medium ("MEM; 
Gibco), supplemented with 5% autologous serum, 4# mM 
L- glutamine (Gibco), 100# U/ml sodium benzylpenicillin G 
(Sigma- Aldrich), 100#%g/ml streptomycin sulphate (Sigma- 
Aldrich) and 20#mM HEPES (N- 2- hydroxyethylpiperazine- 
N!- 2- ethanesulphonic acid), pH 7·2 (Sigma- Aldrich), in a 
humidified atmosphere of 5% CO2/95% air. PBMC or B cells 
were co- cultured with RBC at ratios of 1:1, 1:10 or 1:100 for 
24#h before RBC lysis (RBC Lysis Buffer; BioLegend).
B- cell stimulation
Peripheral blood mononuclear cells or B cells were stimu-
lated with 5#%g/ml anti- human CD40 (BioLegend) and 10#ng/
ml interleukin (IL)- 4 (Sigma- Aldrich) as previously de-
scribed [14], prior to the addition of RBC as required.
Flow cytometry
Flow cytometry was performed using a LSRFortessa™ (BD) or 
FACSDiva™(BD), with data analysed by FlowJo software v10. 
Zombie NIR Viability Dye (BioLegend) was used to exclude 
dead cells from analyses. RBC were identified by staining for 
glycophorin A (anti- CD235a- FITC, BioLegend). Lymphocytes 
were gated based on forward and side scatter and B cells identi-
fied as CD19+ (anti- CD19- PE, BioLegend). Malignant B cells 
from patients with CLL were identified as CD19+ and CD5+.
Activation markers
Cells were washed in flow cytometry staining buffer (BD 
Pharmingen), treated with Fc block (BD Bioscience) and 
stained for flow cytometric analyses of extracellular mark-
ers using fluorochrome- conjugated antibodies according to 
the manufacturer's instructions. Antibodies included anti- 
CD19- PE or anti- CD19- FITC, anti- CD5- BV421 and the 
activation markers anti- HLA- DP, DQ, DR Alexa Fluor 647 
or anti- HLA- DP/DQ/DR- FITC, anti- CD86- PerCP- CY5.5, 
anti- CD69- FITC and anti- CD40- PE- Cy7 (BioLegend); 
markers of maturation anti- CD38- FITC or anti- CD38- APC 
and CD24- APC- Cy7 (BioLegend); or CD22- FITC and 
sialic acid- binding immunoglobulin- like lectin (Siglec)- 10- 
APC (BioLegend). Immunoglobulin isotype- matched con-
trol antibodies were used to confirm specificity of staining. 
Extracellular staining was conducted for 30#min in the dark at 
4°C, before the cells were washed and analysed by flow cy-
tometry. To correct for inter- assay variation, ratios were cal-
culated of staining intensity in treated versus control cultures.
Transwell cultures
Transwell inserts (Corning) with a pore size of 0·4#µm were 
added to the culture plates to prevent translocation of RBC 
(diameter 6– 8# µm). PBMC were added to the plates as de-
scribed above, before addition of transwell inserts and place-
ment of RBC into the upper chamber. After 24#h of incubation, 
cultures from the lower compartment were collected and ana-
lysed for changes in markers of B- cell activation.
Proliferation assay
After 24, 72 or 96#h of co- culture with RBC, B cells that had 
been stimulated with anti- CD40 and IL- 4 were pulsed with 
[3H]- thymidine for 6# h. The samples were then harvested 
using a Tomtec harvester (Tomtec Inc.), and [3H]- thymidine 
incorporation was measured using conventional liquid scin-
tillation procedures (Wallac Microbeta Trilux).[15] Results 
were obtained as counts per minute (cpm), and stimulation 
indices (SI) were determined as the ratios of mean cpm in trip-
licate B- cell cultures with, versus without, addition of RBC.
Immunoglobulin ELISA
Isolated B cells were stimulated with anti- CD40 and IL- 4, or 
left untreated, and cultured with or without RBC for 5#days, 
before the levels of IgG and IgM in culture supernatants 
were measured using human IgG or IgM total ELISA Ready- 
SET- Go! ™ Kit (Invitrogen).
Antigen presentation assay
CD19+ B cells and CD4+ T cells were isolated as described 
above from peripheral blood of healthy donors or patients 
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with CLL. B cells were incubated with, or without, RBC 
for 24#h before pulsing with either the T- cell- dependent pri-
mary antigen keyhole limpet haemocyanin (KLH, 10#µg/ml, 
Sigma- Aldrich), the recall antigen- purified protein deriva-
tive (PPD, 10# µg/ml, Statens Serum Institut, Copenhagen, 
Denmark) or the mitogen concanavalin A (ConA, 10#µg/ml, 
Sigma- Aldrich) for 6#h [15]. RBC were then lysed, antigen 
and RBC debris were washed away, and T cells previously 
stained with carboxyfluorescein succinimidyl ester (CFSE) 
(0·2#µM, Fisher Scientific, Hampton, New Hampshire) were 
added at a 1:1 ratio to B cells and then cultured for 5#days. 
Flow cytometric determination of CFSE dilution in T cells 
(anti- CD4- PerCP- Cy5.5) was used as a measure of their pro-
liferation in response to B- cell antigen presentation, with the 
proportions of T cells that had undergone proliferation com-
pared in the presence versus absence of RBC.
RBC damage
Red blood cells were resuspended in "MEM (1:20, Gibco) and 
were damaged by either heat shock at 56°C for 15#min, treat-
ment with copper sulphate (CuSO4, 0·2#mM, Sigma- Aldrich) 
and ascorbic acid (5#mM, Sigma- Aldrich) for 60#min, or cal-
cium ionophore A23187 (2#µM, Sigma- Aldrich) for 15#min.
Neuraminidase treatment
Sialic acid molecules were depleted from RBC by treating 
with neuraminidases. Both "(2,3)- and "(2,6)- linked sialic 
acids were removed by incubating RBC in "MEM with an 
active recombinant fragment of Vibrio cholerae- derived neu-
raminidase (University of St Andrews, UK) for 30# min at 
37°C, before termination of the reaction by addition of 10% 
fetal calf serum. RBC were selectively depleted of "(2,3)- 
linked sialic acids by treatment with neuraminidase S (New 
England Biolabs) in 1$ Glycobuffer (provided) at 37ᵒC. 
After treatment with either enzyme, RBC were washed and 
resuspended in "MEM before adding to PBMC populations. 
RBC were analysed for sialic acid expression by flow cy-
tometry after staining at room temperature for 30#min with 
the biotinylated lectins Maackia amurensis lectin II (MAL 
II, Vector Laboratories) or Sambucus nigra agglutinin (SNA, 
Vector Laboratories), which bind "(2,3)- or "(2,6)- linked 
sialic acids respectively, followed by development with E- 
Cy7- streptavidin (eBioscience).
Siglec blocking
To identify the activity of the Siglec family of lectins, anti-
bodies were used to block the interaction of particular family 
members with their respective ligands. Polyclonal anti- CD22 
(Antibodies- online), anti- Siglec- 10 (Invitrogen), or the cor-
responding isotype controls, were added at 2·5# µg/ml to B 
cells prior to incubation with RBC.
Statistical analyses
For comparison of two paired groups, non- parametric two- 
tailed Wilcoxon tests were performed. Statistical differences 
between &3 paired groups were determined using Friedman's 
and Dunn's tests. Statistical differences between two un-
paired groups were determined using the Mann– Whitney 
tests. Statistical differences between &3 unpaired groups 
were determined using the Kruskal– Wallis tests. When de-
termining statistical dependence between two variables, non- 
parametric Spearman's rank tests were used. Mean +/- SD are 
shown for all data and two- tailed p- values <0·05 considered 
significant. Data analyses were performed using the Prism 
6.0 software (GraphPad).
RESULTS
RBC exposure down- regulates B- cell activation 
markers
We first tested whether removal of RBC from whole blood 
had any effect on the expression of human B- cell activation 
markers. B cells were identified as CD19+ and changes in 
their phenotype determined by flow cytometry. PBMC were 
separated from RBC, and B- cell expression of HLA- DP/DQ/
DR was measured as a marker of activation at 6 hourly inter-
vals for 24#h and compared with the expression by B cells that 
had remained in paired samples of whole blood. Although 
freshly isolated B cells already stain strongly for HLA- DR/
DP/DQ (Figure S1a), removal of RBC was associated with 
a notable increase in expression, which was significant by 
12#h, and which typically continued to rise throughout the ex-
periment (Figure 1a). These results indicated that B- cell acti-
vation was inhibited by RBC at ratios found in whole blood, 
but for further experiments to define the extent and mech-
anism of suppression, ratios of 1:1 to 1:100 were tested as 
being more practical for cultured cells. Complementing the 
results of fractionating whole blood, reconstitution of PBMC 
with titrations of RBC resulted in corresponding, significant 
decreases in the levels of HLA- DR/DP/DQ expressed by B 
cells (Figure 1b). In the reconstitution experiments, the lev-
els of additional activation markers, CD86, CD69 and CD40, 
were measured on B cells and were also demonstrated to fall 
when RBC were added to PBMC (Figure 1b).
Given this evidence that RBC suppress expression 
of multiple B- cell activation markers, we asked whether 
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reconstitution of PBMC with RBC induced any changes in 
the maturation status of B cells. Characterization of B- cell 
subsets (Figure S1b) based on CD24 and CD38 expression 
[16 did not show any significant changes in the percentages 
of immature, naïve, memory or plasmablast B cells upon ad-
dition of RBC (Figure 1c). Whether RBC suppress activation 
differentially between these peripheral blood subsets was 
determined by staining B cells for both the activation and 
maturation marker sets. Significant RBC suppression of B- 
cell activation markers was observed in immature, naïve and 
memory B cells, with a trend for suppression in plasmablasts 
(Figure 1d).
F I G U R E  1  Exposure to RBC suppresses B- cell expression of activation markers HLA- DP/DQ/DR, CD86 and CD69. Flow cytometry was 
used to determine B- cell expression of activation markers under the following conditions. (a) HLA- DP/DQ/DR expression by B cells in whole 
blood versus in PBMC at intervals after separation from RBC. Representative histogram illustrates HLA- DP/DQ/DR expression in whole blood 
(orange), and 6 (red), 18 (blue) and 24 (purple) hours after separation (n#=#6). Summary graph shows fold change of HLA- DP/DQ/DR expression 
by isolated B cells compared with those in whole blood. The 6 sets of linked points represent data from 6 different healthy donors. **p#<#0·01, 
***p#>#0·001 (Friedman). (b) Isolated RBC were added back to PBMC at ratios of 1:1, 1:10 or 1:100 (B: RBC) and incubated for 24#h before 
determining B- cell levels of HLA- DP/DQ/DR, CD86, CD69 and CD40 expression. Histograms show representative data for HLA- DP/DQ/
DR, CD86, CD69 and CD40 expression in isolated B cells (red) and B cells exposed to 1:100 RBC (blue), compared with the isotype controls 
(orange). Summary results are expressed as fold changes compared with expression on the B- cell- only controls (n#=#10). *p#>#0·05, **p#<#0·01, 
***p#>#0·001 (Friedman). (c) RBC were added to PBMC and incubated for 24#h. CD19+ B cells were then stained for CD24 and CD38 expression 
to assess maturation status. The percentages of B cells within the immature (CD19+CD38hiCD24hi), naïve (CD19+CD38intCD24int), memory 
(CD19+CD38'CD24+) and plasmablast (CD19+CD38'CD24') populations are shown for B cells alone and B cells with RBC exposure (N#=#10). 
(d) Expression of HLA- DP/DQ/DR was determined for each of the maturation subsets and compared in B cells alone compared with B cells 
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We also determined whether the presence of other 
leucocytes in PBMC was necessary for the suppressive 
effect of RBC on B- cell activation markers. When pu-
rified populations of CD19+ B cells were isolated from 
PBMC, their expression of HLA- DP/DQ/DR, CD86 and 
CD40 again fell significantly when cultured together with 
RBC (Figure 2a), indicating that the inhibitory interaction 
between RBC and B cells was independent of any other 
cell type. Another question addressed was whether the 
suppression of activation markers by RBC was also seen 
when B cells were responding to stimulation, and not an 
effect limited to resting cells. When purified B cells were 
stimulated with anti- CD40 antibody and IL- 4, the expres-
sion of HLA- DR/DP/DQ, CD86, CD69 and CD40 rose as 
expected, but the increases were significantly lower in co- 
cultures containing RBC (Figure 2b). Overall, these re-
sults demonstrate that the presence of RBC regulates the 
activation level of B cells, both resting and stimulated, 
and independently from their differentiation status, and 
that this suppressive effect does not require the presence 
of other leucocyte types.
RBC exposure inhibits B- cell function
The next question to be addressed was whether exposure 
to RBC affects B- cell function; in particular proliferation, 
release of immunoglobulin and the ability to present anti-
gen to T cells. When purified, unstimulated CD19+ B cells 
were incubated in the presence of RBC, there were mod-
est but significant decreases in the levels of IgM, but not 
IgG, secreted into the supernatant (Figure 3a). Although 
B cells are relatively short- lived in culture, the levels of 
immunoglobulin are cumulative and therefore represent 
their initial secretory activity. Co- incubation with RBC 
also inhibited proliferative (Figure 3b) and IgM secretory 
(Figure 3c) responses of B cells to anti- CD40 antibody and 
IL- 4, demonstrating that the suppressive effects of RBC 
F I G U R E  2  RBC suppress B cells independently of other leucocytes or stimulation status. Flow cytometry was used to determine B- cell 
expression of activation markers under the following conditions. (a) CD19+ B cells were isolated using negative B- cell isolation beads. RBC were 
added to the cultures at ratios of 1:1, 1:10 or 1:100 (B: RBC) and incubated for 24#h before determining the levels of HLA- DP/DQ/DR, CD86, 
CD69 and CD40 expression on CD19+ B cells (n#=#8). *p#<#0·05, **p#<#0·01 and ***p#=#0·001 (Friedman). (b) B cells stimulated with 5#µg/ml 
anti- human CD40 and 10#ng/ml IL- 4 were co- incubated with 1:1, 1:10 or 1:100 (B: RBC) and incubated for 24#h before determining the levels of 
HLA- DP/DQ/DR, CD86, CD69 and CD40 expression on CD19+ B cells (n#=#8). *p#<#0·05, **p#<#0·01 and ***p#<#0·001 (Friedman). Results are 
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on function were, like those on activation marker expres-
sion, seen in both stimulated and unstimulated B cells. The 
flow cytometric analyses of changes in activation (Figure 
1b) and maturation (Figure 1b) marker and expression are 
consistent with RBC suppressing the B- cell fraction as a 
whole rather than particular subpopulations. Although the 
F I G U R E  3  Exposure to RBC suppresses B- cell IgM secretion and proliferation, and can reduce ability to present antigen. (a) B cells without 
or with RBC (1:100) were incubated for 5#days before levels of IgM and IgG were measured in supernatants by ELISA (n#=#10). **p#<#0·01 
(Wilcoxon). (b) B cells were stimulated with anti- CD40 and IL- 4, and RBC added to cultures (1B:100RBC) and incubated for 24, 48 or 72#h prior 
to 3H- thymidine incorporation. Proliferation results are presented as fold changes of mean counts per minute in B- cell– RBC co- cultures compared 
with B- cell- only cultures (n#=#8). **p#<#0·01 (Wilcoxon). (c) CD19+ B cells were isolated and stimulated with 5#µg/ml anti- CD40 and 10#ng/ml 
IL- 4 before addition of RBC (1B:100RBC). Levels of IgM and IgG were measured in supernatants by ELISA after 5#days of culture. **p#<#0·01 
(Wilcoxon). (d) Flow cytometric determination of the percentage of CFSE- labelled CD4+ T cells that had divided was used as a measure of B- cell 
antigen presentation in cultures of T cells exposed to B cells that had been pulsed with primary antigen PPD or secondary antigen KLH, or stimulated 
non- specifically with ConA in the presence or absence of 1:100 RBC (n#=#10) (Wilcoxon). B, B cells; ConA, concanavalin A; Ig, immunoglobulin; 
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F I G U R E  4  RBC- induced B- cell suppression is contact, sialic acid and Siglec- dependent. Flow cytometry was used to determine B- cell 
expression of activation markers under the following conditions. (a) After 24#h of incubation, HLA- DP/DQ/DR expression on CD19+ B cells was 
compared in B cells cultured alone, co- cultured with RBC, or in cultures with B cells separated from RBC by transwell inserts. Results expressed as 
fold changes compared with B- cell- only cultures (n#=#10). *p#<#0·05 (Friedman). (b) HLA- DP/DQ/DR expression on CD19+ B cells was compared 
after 24#h of culture alone, or co- incubated with RBC that had been treated with neuraminidase or neuraminidase S respectively to remove both 
"(2,3)- and "(2,6)- linked, or only "(2,3)- linked, sialic acids. Results expressed as fold changes compared with B- cell- only cultures (n#=#10). 
**p#<#0·01 (Kruskal– Wallis). (c) HLA- DP/DQ/DR expression was compared on CD19+ B cells that had been treated with blocking anti- CD22 
or anti- Siglec- 10 antibodies, or an isotype control, before 24#h of culture alone, or co- incubated with RBC. Results expressed as fold changes 
compared with untreated B- cell- only control cultures (n#=#10). *p#<#0·05, **p#<#0·01 (Wilcoxon). (d) CD19+ B cells were analysed for expression 
of CD22, and this was correlated with the fold change in HLA- DP/DQ/DR expression after RBC co- culture in individual donors (n#=#17). 
Spearman's r#=#'0·5874, *p#<#0·05. (e) CD19+ B cells were isolated from CLL patients, autologous RBC were added to the cultures at ratios of 
1:1, 1:10 or 1:100 (B: RBC) and incubated for 24#h before determining the levels of HLA- DP/DQ/DR expression on CD19+CD5+ B cells (n#=#10) 
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biological relevance of any of the changes in B- cell func-
tion in vitro remains to established, taken together, these 
data point to RBC as regulators of a wide range of B- cell 
activities.
The ability of RBC to suppress B- cell expression of 
HLA- DP/DQ/DR and CD86, which are two key components 
of the antigen- presenting machinery, prompted us to test 
whether RBC inhibited antigen- presenting function. The pro-
liferation of purified, CFSE- stained CD4+ T cells presented 
with antigen by purified CD19+ B cells was compared after 
the B cells had been incubated in the presence or absence of 
RBC. The proportions of CD4+ T cells proliferating in re-
sponse to the antigens PPD or KLH were reduced when the 
presenting B cells had been preincubated with RBC for cells 
from seven of the ten donors tested, although the fall did not 
achieve statistical significance across the donor group overall 
(Figure 3d). By contrast, suppressive effects of RBC prein-
cubation with B cells on T- cell responses were infrequently 
observed when cultures were stimulated with the mitogen 
concanavalin A, which does not require antigen processing 
and presentation as peptide on MHC class II. Thus, RBC 
suppress a variety of B- cell functions, including prolifera-
tion and IgM secretion, and can inhibit the ability to present 
MHC- dependent antigens in many, but not all, donors.
RBC- mediated B- cell suppression is 
contact and sialic acid- dependent
The next set of experiments characterized the mechanisms 
responsible for RBC regulation of B cells. We first estab-
lished whether the suppression was due to direct cell– cell 
interactions, or the release of soluble factors, by culturing 
purified CD19+ B cells and RBC in the separate chambers 
of a transwell system. When physical contact between co- 
cultured B cells and RBC was prevented in this way, the 
effect of RBC in reducing the expression of the activation 
markers HLA- DP/DQ/DR was lost (Figure 4a).
The dependence of RBC suppression on direct contact 
with B cells raises the question as to the identities of the 
ligand– receptor interactions responsible. Suppression was 
limited to healthy RBC, as RBC modified by oxidation or 
other forms of damage failed to suppress B- cell activation 
(Figure S2). The glycocalyx of RBC is particularly prom-
inent and rich in sialic acids [17], which can be lost when 
RBC membranes have been damaged [18,19], so we tested 
whether the inhibitory effect of RBC on purified CD19+ B 
cells is dependent on these glycans. RBC pretreated with a 
recombinant Vibrio cholerae neuraminidase fragment con-
taining the active site that cleaves both "(2- 3)- and "(2- 
6)- linked terminal sialic acids from the membrane (Figure 
S3a) [20] lost the ability to down- regulate B- cell expres-
sion of HLA- DP/DQ/DR (Figure 4b). RBC pretreated with 
the recombinant enzyme neuraminidase S, which cleaves 
"(2- 3)- but not "(2- 6)- linked terminal sialic acids (Figure 
S3b) down- regulated B- cell expression of HLA- DP/DQ/
DR marginally, an effect that was no longer statistically 
significant (Figure 4b). Thus, these initial mechanis-
tic studies showed that the inhibitory effects of RBC on 
B cells are dependent on direct cell– cell contact between 
the populations, and on the display of sialic acids by RBC, 
with both "(2- 6)- and " (2- 3)- linked sialic acids required 
for optimal suppression.
RBC- mediated B- cell suppression is dependent 
on B- cell CD22, but not Siglec- 10
The dependence of RBC suppression on sialic acids sug-
gested the identities of the B- cell receptors involved. CD22 
and Siglec- 10 are inhibitory co- receptors on B cells [21,22], 
and each acts as a lectin to bind the terminal sialic acid resi-
dues on cell surface glycans. We therefore tested whether 
the inhibitory effect of RBC on purified CD19+ B cells is 
dependent on CD22 or Siglec- 10 recognition of these sug-
ars. The ability of RBC to down- regulate B- cell HLA- DP/
DQ/DR was prevented by the addition of a blocking anti-
body specific for CD22 (Figure 4c), but not an antibody for 
Siglec- 10 (Figure 4c), to co- cultures. In some individuals, 
blocking CD22 on purified B cells in the absence of RBC 
also increased expression of HLA- DR/DP/DQ, but no direct 
stimulatory effects of anti- CD22 antibodies have been re-
corded, and the result is instead consistent with blockade of 
tonic inhibitory signals from CD22 ligation in cis that have 
been reported to arise because the receptor itself is glyco-
sylated and decorated with sialic acids [23].
If CD22 mediates suppression of B cells by RBC, and 
given the observation that expression of this receptor var-
ies markedly between donors (Figure S4a), it would be pre-
dicted that its levels determine the strength of the inhibitory 
effect. This prediction was fulfilled as there is a significant 
positive correlation between CD22 expression on B cells and 
the reduction in HLA- DP/DQ/DR after incubation with RBC 
(Figure 4d). To further test the role of CD22, and to explore 
the relevance of the RBC suppressive mechanism to a human 
disease, we took advantage of findings that the lectin CD22 is 
expressed at only low levels by malignant B cells in patients 
with CLL [24]. We hypothesized that that these low lectin 
levels would result in refractoriness to RBC inhibition and so 
might contribute towards the activated phenotype [9,25] of 
CLL cells. Analyses of peripheral blood samples from cases 
of CLL confirmed that CD19+ B cells with the malignant 
CD5+ phenotype, which predominate in patients’ PBMC, had 
low levels of CD22, and their expression of Siglec- 10 was also 
found to be somewhat reduced (Figure S4b). In contrast to 
the inhibitory effects of RBC on CD19+ B cells from healthy 
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donors, which were replicated for the corresponding minor 
CD5+ CD19+ B- cell fractions (Figure S5a), the addition of 
RBC failed to reduce the expression of HLA- DP/DQ/DR 
(Figure 4e) by CD5+ CD19+ B cells from patients with CLL.
We also asked whether the ability of CLL cells to present 
autoantigen to T cells might resist inhibition by RBC, as CLL 
is closely associated with autoimmune haemolytic anaemia 
(AIHA), and the malignant B cells are effective APC in driv-
ing the pathogenic responses, which most commonly target 
the RhD protein [15]. CD5+ CD19+ CLL B cells were incu-
bated with or without RBC, pulsed with RhD protein, and 
cultured with autologous CD4+ T cells that had been CFSE- 
stained to follow their proliferation. In six of the 11 patients 
tested, exposure of CLL B cells to RBC failed to reduce the 
T- cell proliferative response, but RBC were suppressive in 
the remaining five cases, and lack of inhibition was not re-
lated to whether the patients also exhibited clinical AIHA 
(Figure S5b).
Taken together, these results establish ligation of RBC 
sialic acid by the B- cell lectin receptor CD22 as a key mo-
lecular mechanism in the suppression of B cells by RBC, and 
illustrate that the effectiveness of this mechanism is reduced 
in a human disease characterized by B cells with an activated 
phenotype.
DISCUSSION
Our work has revealed a novel function of RBC, the sup-
pression of B cell activation. RBC were shown to inhibit B- 
cell display of activation markers (HLA- DR/DP/DQ, CD40, 
CD69, CD86), cellular proliferation in response to CD40 and 
IL- 4, and IgM secretion. Our results contribute to current mod-
els of crosstalk between the immune system with other cells 
and demonstrate that RBC functions extend beyond gaseous 
transport to include regulation of immune responsiveness.
RBC- induced suppression of B cells was found to be 
contact- dependent, with a major molecular mechanism 
identified as ligation of sialic acid on the RBC surface by 
the inhibitory B- cell receptor CD22. Both "(2- 3)- and "(2- 
6)- linked terminal sialic acids are abundant as prospective 
ligands on RBC [26], but CD22 recognizes only the latter 
[27]. CD22 ligation with "(2- 6)- linked sialic acids recruits 
the tyrosine phosphatase, Src homology 2 domain- containing 
phosphatase 1, to immunoreceptor tyrosine- based inhibitory 
motifs and so inhibits B- cell receptor- induced calcium sig-
nalling [21], and also inhibits stimulatory signals from other 
innate receptors [28]. The ability of CD22 to bind sialic acid 
has previously been recognized as important in the induction 
of B- cell tolerance to self- antigens, with sialylated glycans 
being characteristic of higher vertebrates but absent on mi-
crobes [29]. The role of trans interactions of CD22 with si-
alic acids in tolerance has been demonstrated using sialylated 
multivalent antigens that were able to bind both the BCR and 
CD22. Exposure to such antigens resulted in the dampening 
of BCR signalling [30]. We now infer that ligation of B- cell 
CD22 by sialic acids on other cell types, such as RBC, can 
also play a role in regulating B- cell activity. This comple-
ments the work of Spiller et al, who showed that the display of 
hen egg lysozyme (HEL) antigen by C57BL/6J mouse RBC, 
which naturally lack CD22 and Siglec- 10 ligands, resulted in 
strong activation of HEL- specific B cells, but that these re-
sponses were lost if synthetic high- affinity ligands had been 
introduced to the RBC membrane [31]. These animal studies 
support the mechanism of B- cell inhibition that we propose, 
but also reveal species differences as, unlike the situation re-
ported in mice, we show that sialic acids naturally displayed 
by human RBC act as effective ligands for inhibitory lectin 
receptors on B cells. CD22'/' gene- deleted mice have been 
widely used to determine the role of CD22 as an inhibitory 
co- receptor on B cells [32]. Further comparison of the de-
tailed phenotype of such mice with our work is problematic 
because they can also carry other unintended genetic changes 
that result in, for example, an intrinsic RBC defect [33].
Although CD22 was determined to be a key B- cell inhibitory 
receptor ligated by sialic acids on human RBC, the suppressive 
effect was no longer significant after RBC were selectively de-
pleted of "(2- 3)- sialic acids, which are not recognized by CD22 
[27]. This raised the possibility of a contribution via another re-
ceptor, Siglec- 10, the candidate B- cell lectin that does bind "(2- 
3)- sialic acids [34], with previous studies demonstrating that 
cells transfected to express this lectin gained the ability to bind 
human RBC in a sialic acid- dependent manner [35]. However, 
any contribution of Siglec- 10 to the suppressive mechanism we 
describe appears minor, as RBC retain a significant inhibitory 
effect on B cells after blockade of this receptor.
We propose that RBC suppress human B cells in order to 
prevent their activation in an inappropriate environment, the 
bloodstream. This effect is dependent on continued physical 
contact and therefore would be lost to allow the full respon-
siveness of B cells when they migrate into tissues such as 
SLO, which provide the cellular architecture necessary for 
the activation and control of adaptive immune responses [36]. 
Sialic acids are widely expressed on human cellular surfaces, 
but the density and diversity of sialylated glycans on RBC 
[17] may equip them to be particularly effective immune reg-
ulators in the bloodstream.
Activation of adaptive immune cells such as B cells out-
side SLO in the bloodstream may not only be inefficient in 
generating protective immunity, but could compromise con-
trol of unwanted or damaging B- cell function in autoimmune 
or neoplastic disease. There is evidence that ineffective CD22 
and Siglec- 10 ligation contribute to disease. For example, 
CD22 polymorphisms are reported to predispose to autoim-
munity, with the low- expressing allele CD22a found in strains 
such as the lupus- prone BXSB mice [37]. Furthermore, an 
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autoimmune phenotype involving high levels of autoantibody 
and mild glomerulonephritis was found in ageing C57BL/6 
mice with Siglec- 10 deficiency [38]. Here, we demonstrate 
ineffective interactions between RBC and CLL B cells, which 
express low levels of CD22. CLL B cells were found to be re-
fractory to the down- regulatory effects of RBC on activation, 
which may be a previously unrecognized factor contributing 
to the activated phenotype of CLL B cells.
Whether RBC inhibit antigen presentation by healthy B 
cells, in addition to suppressing other signs of activation, 
differed between donors. Furthermore, although effects in 
individual patients cannot be ruled out, there was no clear 
evidence that failure of RBC to regulate CLL B cells contrib-
utes to their ability [15] to present autoantigen and so promote 
autoimmune complications such as AIHA in CLL. In several 
patients, RBC did not block CLL B- cell presentation of RhD 
protein, the major autoantigen in AIHA, but, as above, com-
parable results were also obtained with foreign antigen and 
healthy B cells in some donors, and there also was no cor-
relation with the diagnosis of concurrent AIHA. However, 
subclinical autoimmunity is common in CLL [11] and may 
confound this analysis. Low expression of CD22 may be 
compensated for by other mechanisms for regulating B- cell 
activation in particular individuals. For instance, Giovannone 
et al recently demonstrated a role for the immunomodulatory 
lectin galectin- 9 (Gal- 9) in BCR signalling and regulation by 
ligating CD45 on naïve B cells [39].
RBC have been reported to exert modulatory effects on 
neutrophils [5], monocytes [40] and T cells [6]. Neutrophil ac-
tivation was shown to be dampened by RBC sialic acids in-
teracting with the inhibitory receptor Siglec- 9 [5], and RBC 
induced immunosuppressive effects on healthy monocytes in 
an in vitro model of RBC transfusion [40]. A suppressive ef-
fect on lymphocytes has been shown with RBC significantly 
suppressing mitogen- stimulated human T- cell proliferation in a 
dose- dependent manner [6], and a suppressive effect on antigen- 
presenting cells has also been observed: a subset of dendritic 
cells (DC) known as slanDC are early- producers of IL- 12 and 
are found at high frequencies in type 1T helper cell- associated 
inflammatory diseases. Ligation of signal- regulatory protein 
" on slanDC by CD47 on RBC in the bloodstream inhibited 
the maturation and pro- inflammatory effects of these cells [41].
Overall, this work helps to develop the paradigm that 
RBC regulate immune cells. Our demonstration that RBC 
suppress a major arm of the adaptive immune system, the 
B- cell compartment, suggests a model whereby RBC are im-
portant general regulators of immune cells whilst they are 
circulating in the bloodstream.
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